Johnson & Johnson to Acquire Abiomed

November 1, 2022 — Johnson & Johnson and Abiomed, a world leader in breakthrough heart, lung and kidney support technologies, today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstand
DAIC's Top 10 for the month of October

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional cardiology during the month of October.

1. AHA Scientific Sessions 2022 Program, Late-breakers Announced

2. Image Gallery Showing Impact of the COVID-19 Pandemic

October 31, 2022 — Results from the Late-Breaking Clinical Trials session at The VEINS Conference in Las Vegas, NV, were announced on Oct.

October 31, 2022 —  The Yale School of Medicine announced the passing of Robert W. Berliner Professor Emeritus of Medicine Barry L. Zaret, MD, MASNC, professor of internal medicine (cardiology) and of diagnostic radiology, on October 20 at age 82. Dr.

October 31, 2022 —  Several recent discoveries show that the accuracy of diagnosing coronary artery disease and predicting patient risk is improved with the help of artificial intelligence (AI) models developed by scientists in the 

October 31, 2022 —  Atrial fibrillation – a form of irregular heartbeat, or arrhythmia – leads to more than 454,000 hospitalizations and nearly 160,000 deaths in the United States each year. Globally, it is estimated that approximately 60 million people are affected by the condition. 

October 28, 2022 —  V-Wave, announced today the completion of enrollment in RELIEVE-HF, a prospective, randomized, double-blinded, sham-controlled, multi-center pivotal clinical trial.  The RELIEVE-HF study is assessing the safety and effectiveness of the V-Wave Ventura\ Interatrial Shunt for the treatment of heart failure (HF) with the potential to reduce future hospitalizations

October 28, 2022 —  SELUTION SLR, MedAlliance’s novel sirolimus-eluting balloon, has received FDA Investigational Device Exemption (IDE) approval to initiate its coronary pivotal clinical trial. This is the first sustained limus release coronary drug eluting balloon (DEB) to receive FDA IDE approval for In-stent Restenosis (ISR) indication. The study has already begun enrollment in Europe. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now